Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study

por Alam, Imtiaz, Brown, Kimberley, Donovan, Cynthia, Forlenza, Jamie, Lauwers, Kris, Mah’moud, Mitchell A., Manch, Richard, Mohanty, Smruti R., Prabhakar, Avinash, Reindollar, Robert, DeMasi, Ralph, Slim, Jihad, Tandon, Neeta, Villadiego, Shirley, Naggie, Susanna
Publicado 2016

Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis

por Poordad, Fred, Sedghi, Shahriar, Pockros, Paul J., Ravendhran, Natarajan, Reindollar, Robert, Lucey, Michael R., Epstein, Michael, Bank, Leslie, Bernstein, David, Trinh, Roger, Krishnan, Preethi, Polepally, Akshanth R., Unnebrink, Kristina, Martinez, Marisol, Nelson, David R.
Publicado 2019

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment

por Poordad, Fred, Felizarta, Franco, Asatryan, Armen, Sulkowski, Mark S., Reindollar, Robert W., Landis, Charles S., Gordon, Stuart C., Flamm, Steven L., Fried, Michael W., Bernstein, David E., Lin, Chih‐Wei, Liu, Ran, Lovell, Sandra S., Ng, Teresa I., Kort, Jens, Mensa, Federico J.
Publicado 2017

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure

por Poordad, Fred, Pol, Stanislas, Asatryan, Armen, Buti, Maria, Shaw, David, Hézode, Christophe, Felizarta, Franco, Reindollar, Robert W., Gordon, Stuart C., Pianko, Stephen, Fried, Michael W., Bernstein, David E., Gallant, Joel, Lin, Chih‐Wei, Lei, Yang, Ng, Teresa I., Krishnan, Preethi, Kopecky‐Bromberg, Sarah, Kort, Jens, Mensa, Federico J.
Publicado 2018